Skip to main content

ndv-01

Generic: gemcitabine and docetaxel

ndv-01: 3 clinical trials tracked.

ndv-01 evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about ndv-01, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (3)

A Phase 3 Study Evaluating the Efficacy and Safety of NDV-01 in Participants With Non-muscle Invasive Bladder Cancer (RESCUE)

NCT07464145Registry updated 2026-09-02·Phase 3·RLMD
Not yet recruiting

Primary endpoint: Disease Free Survival in participants with Intermediate Risk NMIBC

InterventionalRandomizedopen393 targetStarted 2027-02Completion 2032-12Relmada Therapeutics, Inc.

A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

NCT07342517Registry updated 2026-03-17·Phase 3·RLMD
Withdrawn

Primary endpoint: To evaluate the efficacy of NDV-01 (determined by complete response [CR] anytime) administered by intravesical instillation in patients with BCG-unresponsive NMIBC who have recurred after first-line intravesical therapy (approved or in development).

Interventionalopen0 targetStarted 2026-06Completion 2028-06Relmada Therapeutics, Inc.

A Phase 3, Randomized Study Evaluating the Efficacy and Safety of NDV-01 Versus Observation in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (BOOST)

NCT07313891Registry updated 2026-03-17·Phase 3·RLMD
Withdrawn

Primary endpoint: To compare DFS between study arms

InterventionalRandomizedopen0 targetStarted 2026-05Completion 2029-11Relmada Therapeutics, Inc.